摘要
目的:探讨通过罗沙司他与重组人促红细胞生成素对维持性腹膜透析患者血脂的影响。方法:收集2020年9月至2021年9月,海南医学院第二附属医院收治的腹膜透析患者作为研究对象(透析时间3个月以内),合并有肾性贫血,符合纳入标准的患者70例,随机分成观察组35例及对照组35例。观察组给予罗沙司他胶囊治疗3月,对照组给予重组人促红细胞生成素治疗3月。收集治疗前和治疗3月之后化验指标,包括RBC,HB,HCT,TC,LDL-C,HDL-C,TG等指标。结果:两组患者基线临床资料及实验室指标无统计学差异;两组患者治疗后Hb,RBC,HCT比治疗前均出现明显升高,差异具有统计学意义(P < 0.01),且观察组Hb,RBC,HCT较对照组数值高,差异具有统计学意义(P < 0.01)。观察组患者贫血治疗总有效率为97.14%,高于对照组的68.57% (P < 0.05);观察组治疗后TC、LDL-C、HDL-C均比治疗前明显下降,差异具有统计学意义(P < 0.05),且TC、LDL-C与对照组相比明显降低差异统计学意义(P < 0.01)。结论:罗沙司他治疗腹膜透析肾性贫血疗效不低于重组人促红细胞生成素,同时可以改善脂代谢。
Objective: To investigate the effect of Roxadustat and recombinant human erythropoietin on blood lipid in maintenance peritoneal dialysis patients. Methods: Peritoneal dialysis patients with renal anemia admitted to the Second Affiliated Hospital of Hainan Medical University from September 2020 to September 2021 were collected as research objects (dialysis duration less than 3 months). The observation group was treated with Roxadustat capsule for 3 months, and the control group was treated with recombinant human erythropoietin for 3 months. Laboratory indicators including RBC, HB, HCT, TC, LDL-C, HDL-C and TG were collected before treatment and 3 months after treat-ment. Results: There was no statistical difference in baseline clinical data and laboratory indexes between the two groups;After treatment, Hb, RBC and HCT were significantly higher in both groups than before treatment, with statistical significance (P < 0.01), and Hb, RBC and HCT values in the observation group were higher than those in the control group, with statistical significance (P < 0.01). The total effective rate of anemia treatment in observation group was 97.14%, which was higher than 68.57% in control group (P < 0.05). After treatment, TC, LDL-C and HDL-C in the obser-vation group were significantly decreased compared with before treatment, with statistical signifi-cance (P < 0.05), and TC, LDL-C were significantly decreased compared with the control group (P < 0.01). Conclusion: Roxadustat is no less effective than recombinant human erythropoietin in the treatment of peritoneal dialysis renal anemia and can improve lipid metabolism.
出处
《临床医学进展》
2023年第5期7537-7543,共7页
Advances in Clinical Medicine
